7 completed, 3 active not recruiting, 2 unknown, 1 recruiting. 3 Not applicable, 3 Phase 2, 3 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Active not recruiting 2, Completed 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 4 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Angiomyolipoma: new trials by email Literature Review of Angiomyolipoma trials Research Report on Angiomyolipoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Superselective Renal Artery Embolization for Renal Angiomyolipoma Selective endovascular embolization of kidney artery - Selective Endovascular Embolization of Kidney Artery | Active not recruiting | Botkin Hospital | 50 | 2026-04-06 | 2026-04-20 | |
| Ivonescimab in the Treatment of Multiple Advanced Tumors Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma | Phase 2 | Recruiting | Fudan University | 400 | 2024-11-20 | 2025-08-24 |
| Evaluation of a Simple-Prep Controlled Embolic GPX® Embolic Device - Embolization, Vascular Tumor | Not applicable | Active not recruiting | Fluidx Medical Technology, Inc. | 114 | 2024-11-18 | 2026-03-30 |
| A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) Everolimus - Renal Angiomyolipoma | Phase 4 | Completed | Novartis Pharmaceuticals | 10 | 2023-05-01 | 2026-11-09 |
| Molecular Characterization of Perivascular Epithelioid Cell Tumors Perivascular Epithelioid Cell Tumor, Malignant | Unknown | University Hospital, Strasbourg, France | 100 | 2019-12-01 | 2022-11-15 | |
| Biomarkers of Renal Cancer Renal Cell Carcinoma, Tumor, Solid | Unknown | Biorek S.R.L. | 1000 | 2019-06-11 | 2023-03-27 | |
| MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers multiparametric and fat-detection magnetic resonance imaging (MRI) - Kidney Neoplasms | Not applicable | Active not recruiting | Chang Gung Memorial Hospital | 44 | 2019-02-11 | 2026-03-20 |
| Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. Everolimus - Renal Angiomyolipoma | Phase 4 | Completed | Novartis Pharmaceuticals | 40 | 2018-11-09 | 2021-09-09 |
| Biomarkers for Tuberous Sclerosis Complex (BioTuScCom) Hypomelanotic Macules, Facial Angiofibroma | Terminated | CENTOGENE GmbH Rostock | 20 | 2018-08-01 | 2023-02-10 | |
| EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications Easyx - Varicocele, Endoleak | Not applicable | Completed | Assistance Publique - Hôpitaux de Paris | 50 | 2018-03-30 | 2020-10-09 |
| Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Tuberous Sclerosis, Lymphangioleiomyomatosis | Completed | InCor Heart Institute | 200 | 2016-04-01 | 2022-08-04 | |
| A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa BEZ235 - Malignant PEComa (Perivascular Epithelioid Cell Tumors) | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2012-09-01 | 2013-08-02 | |
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Everolimus (RAD001), Everolimus Placebo - Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM) | Phase 3 | Completed | Novartis Pharmaceuticals | 118 | 2009-04-01 | 2017-02-17 |
| Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis Sirolimus - Angiomyolipoma | Phase 4 | Completed | Fundacio Puigvert | 18 | 2008-10-01 | 2012-03-08 |
| RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS Rapamycin - Nonmalignant Neoplasm, Tuberous Sclerosis | Phase 2 | Completed | Dana-Farber Cancer Institute | 36 | 2005-12-20 | 2022-04-25 |
Tuberous Sclerosis (7) · Lymphangioleiomyomatosis (5) · Carcinoma, Renal Cell (3) · Perivascular Epithelioid Cell Neoplasms (3) · Astrocytoma (2) · Kidney Neoplasms (2) · Neoplasms (2) · Adenoma, Oxyphilic (1) · Bone Neoplasms (1) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Transitional Cell (1) · Endoleak (1)
Neoplasms by Histologic Type (15) · Neoplasms, Adipose Tissue (15) · Neoplasms, Connective and Soft Tissue (15) · Neoplasms (13) · Perivascular Epithelioid Cell Neoplasms (12) · Congenital Abnormalities (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Hamartoma (7) · Heredodegenerative Disorders, Nervous System (7) · Malformations of Cortical Development, Group I (7) · Neoplasms, Multiple Primary (7) · Neoplastic Syndromes, Hereditary (7) · Nervous System Diseases (7) · Nervous System Malformations (7)
Everolimus (3) · Sirolimus (2) · dactolisib (1)
Novartis Pharmaceuticals (4) · Assistance Publique - Hôpitaux de Paris (1) · Biorek S.R.L. (1) · Botkin Hospital (1) · CENTOGENE GmbH Rostock (1) · Chang Gung Memorial Hospital (1) · Dana-Farber Cancer Institute (1) · Fluidx Medical Technology, Inc. (1) · Fudan University (1) · Fundacio Puigvert (1) · InCor Heart Institute (1) · University Hospital, Strasbourg, France (1)
France (3) · Spain (3) · United States (3) · Canada (2) · China (2) · Italy (2) · Russia (2) · Taiwan (2) · Albania (1) · Brazil (1) · Egypt (1) · Georgia (1) · Germany (1) · India (1) · Japan (1)
Carlos Roberto Ribeiro Carvalho, MD, PhD (1) · Francesco Montorsi (1) · Hongxia Wang, Doctor (1) · Li-Jen Wang, M.D., M.P.H. (1) · Michael Darcy, MD (1) · Peter Bauer, Prof.Dr (1) · Roser Torra, MD,PhD (1) · Sandra Dabora, MD, PhD (1) · Vigen Malkhasyan, Doctor of Medical Sciences (1)
PMID 21915260, PMID 23140536, PMID 23437092, PMID 25684695, PMID 26156073, PMID 29023494, PMID 30053159, PMID 30192751
2008 (1), P30CA006516 (1), R01CA107164 (1)